patients hospitalized and treated with this drug have a higher likelihood of being back home a month after the start of treatment, according to a study.
This is a study, the French, who did not see entirely a bad eye on hydroxychloroquine. This derivative of the antimalarial drug chloroquine is usually used to treat autoimmune diseases such as lupus. According to this study, patients hospitalized for Covid-19 and treated with hydroxychloroquine have a higher probability of being returned home a month after the start of treatment.
“The exit rates of hospitalization significantly higher levels were observed in patients treated with hydroxychloroquine,” the study concludes online Saturday, but not yet published. The rate of patients who returned to their home 28 days after the start of treatment is higher by 11 points to those who have not received the drug. This represents a relative increase of 25 % of the probability to be released from hospitalization, the study says.
READ ALSO >> Didier Raoult : “in The beginning, I had doubts about the chloroquine, but more now”
Your support is essential. Subscribe for $ 1 support Us
This result, which had not been highlighted in previous research on hydroxychloroquine, “deserves to be replicated in other studies of large-scale” to be confirmed, stressed one of the autrices of this study, Emily Sbidian, questioned by the AFP. Authorization of prescription of hydroxychloroquine to the hospital, outside of clinical trials, was withdrawn on 4 may. WHO has stopped tests on hydroxychloroquine.
The researchers analyzed the medical records of approximately 4642 patients hospitalized for Covid-19 in one of the 39 hospitals the AP-HP between 1 February and 6 April. They excluded those who had received another drug currently being tested against the sars coronavirus, as the antiviral remdesivir or immunosuppressive tocilizumab and sarilumab.
lack of effectiveness to reduce mortality
The results were adjusted statistically to take into account the “confounding factors”, and in particular the difference in the composition of the three groups. “Regarding the data of our study, we can thus see that the patients on hydroxychloroquine or hydroxychloroquine/azithromycin exhibited rates of obesity, diabetes, and smoking (bad prognostic factors) highest in the order of 5 % to 15 %, but they were also much younger than the patients not treated with hydroxychloroquine (in the order of six to eight years younger), this can also greatly affect the results, since the mortality of infection with coronavirus is all the more important that the age is high,” explains Émilie Sbidian.
READ ALSO >> Hydroxychloroquine and Covid-19 : “It was necessary to rescue our fellow citizens of this madness”
“so It is very important not to stop with the raw results to judge the effectiveness or ineffectiveness” of the treatment, adds the researcher, dermatologist at the hospital Henri-Mondor in Créteil.
Read our complete file
Covid-19 : hydroxychloroquine
Covid-19 : Jean-Dominique Michel, an expert self-proclaimed war against the science Covid-19 : Test Discovery, the why of a flop French Hydroxychloroquine and Covid-19 : “We had to rescue our fellow citizens of this madness”
The study concludes that in contrast to “the absence of a statistically significant difference in mortality at 28 days between patients who received hydroxychloroquine group and the control group, “after taking into account confounding factors”. Those who received the antibiotic azithromycin, in addition to the hydroxychloroquine, the study observes no difference on the output rate of hospitalization and a possible excess risk of mortality”.
